Visiongain has published a new report entitled Clinical Trial Supply and Logistics Market for Pharma 2025-2035 (Including Impact of U.S. Trade Tariffs): Forecasts by by Type (CTS Manufacturing, CTS Logistics & Distribution, CT Supply Chain Management, CTS Packaging & Storage), by Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV, Post Launch) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.

The clinical trial supply and logistics market for pharma is estimated at US$16.55 billion in 2025 and is projected to grow at a CAGR of 10.1% during the forecast period 2025-2035.

Impact of the U.S. Trade Tariffs on the Global Clinical Trial Supply and Logistics Market for Pharma 

The introduction of U.S. trade tariffs has placed additional strain on the Clinical Trial Supply and Logistics (CTSL) market for pharma, particularly by driving up the cost of imported raw materials, packaging components, and temperature-sensitive equipment. For pharmaceutical companies and their supply chain partners, these increased costs translate into tighter margins and greater complexity in managing global trial operations. With clinical trials already demanding high levels of precision, compliance, and time-sensitivity, any disruption or cost inflation risks delaying studies and raising overall development expenses.

In response, many organisations are reassessing their sourcing strategies, shifting towards alternative suppliers and exploring regional hubs to minimise exposure to tariff-related cost fluctuations. This adjustment not only diversifies risk but also promotes resilience in clinical trial logistics. However, the transition is not without challenges, as ensuring quality consistency, regulatory compliance, and uninterrupted supply chains across multiple geographies requires substantial investment and coordination. Ultimately, tariffs are accelerating a broader shift in how pharmaceutical supply chains are structured, encouraging more agile and globally balanced models.

Stringent Regulatory Oversight Creates Operational Restraints

Compliance with regulatory frameworks such as FDA, EMA, and ICH guidelines presents a persistent challenge for CTSL providers. Each jurisdiction demands unique documentation, labelling, and temperature monitoring, which raises operational costs and risks of delays. Non-compliance can result in fines, shipment rejections, or even trial suspension. For multinational studies, alignment across regions is particularly complex, especially when regulations evolve rapidly.

While sponsors continue to expect efficiency, providers cannot compromise on Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP). Striking this balance consumes significant resources and reduces operational flexibility, often limiting smaller logistics firms from competing effectively in large-scale global studies.

How will this Report Benefit you?

Visiongain’s 272-page report provides 117 tables and 129 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the clinical trial supply and logistics for pharma market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Clinical Trial Supply and Logistics for Pharma. Get financial analysis of the overall market and different segments including type, phase and capture higher market share. We believe that there are strong opportunities in this fast-growing clinical trial supply and logistics for pharma market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Rising Adoption of Cold Chain Solutions Enhances Market Growth

Biologics, cell and gene therapies, and RNA-based treatments dominate the current R&D pipeline, driving demand for ultra-reliable cold chain logistics. Many investigational products require storage at -80°C or even cryogenic conditions. The sensitivity of these products leaves no margin for error, placing immense responsibility on logistics partners to safeguard stability from production to administration.

Real-time IoT monitoring, redundant cold storage, and validated packaging solutions are now essential. Providers investing heavily in advanced cold chain infrastructure are well positioned to capture contracts from sponsors who prioritise quality, compliance, and patient safety above all else.

Outsourcing Trends Strengthen Market Expansion

Pharma and biotech companies are outsourcing more CTSL activities to specialist providers, seeking cost reduction, global reach, and regulatory expertise. Emerging biotechs, in particular, lack the infrastructure to manage complex supply chains, making them highly reliant on outsourcing. CROs and logistics specialists offering integrated services—from comparator sourcing to packaging and distribution—are gaining traction. This trend is accelerating market growth and driving consolidation, as large players acquire niche providers to expand both their service breadth and geographic coverage.

Where are the Market Opportunities?

Decentralised Trials Unlock New Opportunities for Supply Chain Innovation

The surge in decentralised clinical trials (DCTs) is reshaping how investigational products are distributed. Instead of relying solely on central depots, CTSL providers must now support direct-to-patient (DTP) deliveries, integrate home healthcare services, and ensure real-time monitoring of patient compliance.

This shift is opening opportunities for logistics providers to diversify into last-mile delivery and digital patient engagement platforms. Companies capable of designing flexible supply models that integrate telehealth, wearable device data, and courier networks are gaining a significant competitive edge. DCT-driven logistics innovation is emerging as a clear growth frontier for the industry.

Digitalisation and AI Transform Supply Chain Visibility

Technology adoption is becoming a defining trend in CTSL. AI-powered demand forecasting minimises wastage, while blockchain ensures immutable regulatory records. Real-time dashboards enable sponsors to track product movement, temperature excursions, and site inventories. Predictive analytics further reduce the risk of stockouts or over-supply.

These digital solutions not only optimise efficiency but also reinforce transparency, strengthening sponsor confidence. In an increasingly competitive market, providers that deliver AI-augmented and digitally integrated services are emerging as strategic enablers of resilient and scalable trial supply chains.

Competitive Landscape

The major players operating in the clinical trial supply and logistics market for pharma are Catalent, Inc., Thermo Fisher Scientific Inc., ICON plc, Eurofins Scientific, FedEx, United Parcel Service, Inc., Kerry Logistics Network Limited, Kuehne+Nagel, Bilcare Limited, Mayne Pharma Group Limited, Intertek Group plc, Almac Group, Parexel International Corporation, Biocair, Marken (A UPS Company), PCI Pharma Services (PCI), Movianto, Yourway, COREX Logistics, and Oximio, Royal Cargo, and NAF Pharma. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.

Recent Developments

• On 22 March 2025, the Canadian federal government announced up to CAD 40 million in funding to support the expansion of OmniaBio’s cell and gene therapy (CGT) manufacturing facility at McMaster Innovation Park in Hamilton, Ontario.
• On 16^th July 2024, Catalent, Inc. expanded its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent’s flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.